Telix Pharmaceuticals Limited
ASXTelix Pharmaceuticals enters September with a stock down 5.5% on the week yet carrying a month-long gain of 7.5% — a split picture that captures the tug-of-war between improving fundamentals and a short book that refuses to go away. The clearest story in the data is the gradual unwinding of short positions. Short interest has fallen roughly 11% over the past month, dropping from…
Snapshot as of 2 Sept 2026
Telix Pharmaceuticals enters September with a stock down 5.5% on the week yet carrying a month-long gain of 7.5% — a split picture that captures the tug-of-war between improving fundamentals and a short book that…
Telix Pharmaceuticals heads into its May 21 results with one of the most contested short books in Australian biotech — and a CEO who has been quietly buying into the weakness. Short sellers remain heavily positioned.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TLX — free to start on ORTEX.
Sign up for free →Open TLX on ORTEX